Clinical Trial Update: Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant camrelizumab with cisplatin and nab-paclitaxel in resectable head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN